Innate Pharma S.A. (EPA:IPH)

Market Cap	141.38M
Revenue (ttm)	12.64M
Net Income (ttm)	-46.05M
Shares Out	92.17M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	8.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,939
Average Volume	113,291
Open	1.544
Previous Close	1.552
Day's Range	1.530 - 1.580
52-Week Range	1.330 - 2.500
Beta	0.51
RSI	35.21
Earnings Date	Mar 26, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 181
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPH

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.